Navigation Links
Clinicians Ordering Inappropriate Prostate Screenings

According to a report in the July 9 issue of Archives of Internal Medicine, one of the JAMA/Archives journals , Prostate-specific antigen (PSA) tests to screen for prostate cancer are frequently performed among patients for whom the PSA test is not shown to be beneficial, and clinicians with certain characteristics are more likely to order such inappropriate screening tests.

Most guidelines for clinical practice do not recommend routine PSA screening for men younger than 40, older than 75 or who are expected to live less than 10 years, according to background information in the article.

To our knowledge, there is currently no solid evidence that PSA screening provides any health benefits for these patient populations, the authors write.

Rather, it imposes substantial psychological and financial costs and may lead to diagnostic and therapeutic procedures of questionable benefit.

Because the ultimate decision to perform PSA testing rests with the clinician, it is likely that demographic and other characteristics of physicians, nurses and physician assistants may influence inappropriate screening behaviors.

B. Price Kerfoot, M.D., Ed.M., of the Veterans Affairs Boston Healthcare System and Harvard Medical School, Boston, and colleagues analyzed data from 105,765 male patients who were treated at Veterans Health Affairs (VHA) facilities in New England from 1997 to 2004. Information about the patients and the 1,552 health care clinicians who ordered PSA tests was gathered from VHA databases.

Inappropriate screening was defined as PSA testing in patients older than 75 or younger than 40 who had not been diagnosed with prostate cancer, were not taking prostate cancerspecific medications or had not undergone related procedures.

Of the 232,302 PSA tests ordered during the study period, 37,483 (16.1 percent) were considered inappropriate, with 35,612 (15.3 percent) performed in patients older than 75 years and 1,871 (0.8 percent) in patients younger than 40 years.

Of the health care clinicians who ordered inappropriate tests, 51.3 percent were male, 79.4 percent were physicians, 53.4 percent were trainee physicians and 8.2 percent were urologists.

Practitioners who were urology specialists, male, infrequent PSA tests orderers and affiliated with specific hospitals had significantly higher levels of inappropriate PSA screening. Compared with attending physicians, nurses and physician assistants had significantly lower levels of inappropriate screening, the authors write.

The percentage of inappropriate PSA screening increased significantly with the age of male health care providers, they continue.

The cause of these sex and age differences is not clear. It is possible that, as they age, male health care providers increasingly empathize with their older male patients over prostate cancer concerns. Their prostatemphathy may then lead to more aggressive screening in these older male patients.

Patient education and systems-level changes, such as a computerized system that could alert clinicians when they attempt to order an inappropriate PSA test, could help reduce the level of PSA screening misuse, the authors conclude.

For more information, contact JAMA/Archives Media Relations at 312/464-JAMA (5262) or e-mail mediarelations@jama-archives.org


'"/>




Related medicine news :

1. Clinicians Participating In the Pharmaceutical-Sponsored Trails Tend To Prescribe Their Drugs
2. More Elderly Take Inappropriate and Harmful Medications
3. Does Your Prescription Have An Inappropriate Medicine?
4. Elders in Scotland Inappropriately Charged For Free Food
5. Studies Reveal Inappropriate Use Of Drug-Coated Stents
6. Cancer Doctors Okays Controversial Prostate Therapy
7. Radioactive Seeds used in Prostate Cancer treatment can migrate with the body
8. New Prostate Cancer Vaccine Shows Promise
9. Hormone Therapy applicable for Prostate Cancer
10. Prostate cancer and Vitamins
11. Response to chemotherapy could be measured by Prostate-Specific Antigen Doubling Time
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/13/2016)... ... , ... Valentine’s Day is nearly upon us, and most singles could probably ... flawless hair, and a sparkling personality are all well and good, but if somebody ... home with Rover. (Actually, man’s best friend might not even want to be near ...
(Date:2/13/2016)... ... February 13, 2016 , ... In its newly ... vein visualization technology should be used to ensure patient safety when placing an ... INS Standards mandate the use of vein visualization technology in patients with difficult ...
(Date:2/12/2016)... ... 12, 2016 , ... According to an article published February 4th ... significant portion of hernia repairs throughout the United States. Commenting on this article, Beverly ... that this trend has not only been expected, but it seems to be a ...
(Date:2/12/2016)... ... February 12, 2016 , ... CDRH Enforcement Trends: , Back to the Future , ... , As Winston Churchill said, “Those who don’t learn from history are doomed to ... expect when they come knocking this year. But that takes time. , Take a ...
(Date:2/12/2016)... ... February 12, 2016 , ... T.E.N., a ... closed for the ISE Southeast Awards 2016. Finalists and winners of the ISE® ... Southeast Executive Forum and Awards Gala on March 15, 2016 at the Westin ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... February 12, 2016 ... vermerkt)   http://www.sedar.com ) und ... abrufbar.    --> http://www.sedar.com ... http://www.telestatherapeutics.com abrufbar.    --> ... heute seinen Konzernabschluss des zweiten Quartals ...
(Date:2/12/2016)...  Memorial Hermann Health System has teamed up with ... bring a one-of-a-kind experience to pediatric patients at ... as 360-degree video and Google Cardboard, Howard was able ... giving the patients and their families an unexpected, and ... on video . Memorial Hermann IRONMAN ...
(Date:2/12/2016)... , Feb. 12, 2016  Eli Lilly and Company ... Court decided the Alimta® (pemetrexed disodium) vitamin regimen patent would ... the UK, France , Italy ... to dilute the product only with dextrose solution.  ... 2015, the UK Court of Appeal held that Lilly,s patent ...
Breaking Medicine Technology: